April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Degradable Polyesteramides: A New Platform for Ophthalmic Drug Delivery
Author Affiliations & Notes
  • K. A. Messier
    Drug Delivery, DSM Biomedical, Geleen, The Netherlands
  • A. Dias
    Drug Delivery, DSM Biomedical, Geleen, The Netherlands
  • G. Mihov
    Drug Delivery, DSM Biomedical, Geleen, The Netherlands
  • B. Turnell
    MediVas, San Diego, California
  • Footnotes
    Commercial Relationships  K.A. Messier, DSM Biomedical, E; A. Dias, DSM Biomedical, E; G. Mihov, DSM Biomedical, E; B. Turnell, DSM Biomedical, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5314. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. A. Messier, A. Dias, G. Mihov, B. Turnell; Degradable Polyesteramides: A New Platform for Ophthalmic Drug Delivery. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5314.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Amino acid-based polyesteramides (‘PEAs") are being developed as a new biomaterial for ocular drug delivery. PEAs are highly versatile with respect to physico-chemical properties and processability, and hold promise as a sustained release delivery system for ophthalmology.


PEAs are based on α-amino acids, aliphatic dicarboxylic acids and aliphatic α-ω diols and are prepared at DSM Biomedical. These polyester amides have been chemically modified and formulated to provide sustained release of small molecules and biologics from a variety of forms ranging from solid monoliths (such as rods) to coatings and nanoparticles. Degradation profiles are currently being assessed in the intravitreal and sub conjunctival spaces.  


PEAs have been processed into various injectable forms for intra and periocular delivery through small gauge needles. PEAs degrade enzymatically as demonstrated with chymotrypsin, esterases, lipases as well as macrophage meditated degradation. Due to this enzymatic degradation and consequential surface erosion, drug release mainly follows zero-order kinetics. The biocompatibility of PEAs have been studied extensively in preclinical evaluations and have been used clinically in cardiovascular applications. In-vivo degradation profiles of pre-formed rod implants are on-going.


Amino acid based biodegradable polymers represent a next generation platform for sustained release drug delivery and hold promise for utility in ophthalmology.

Keywords: retina • vitreous • conjunctiva 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.